Perceptive Advisors 13F annual report
Perceptive Advisors is an investment fund managing more than $4.14 trillion ran by Joseph Edelman. There are currently 104 companies in Mr. Edelman’s portfolio. The largest investments include Cerevel Therapeutics Hldng I and Amicus Therapeutics Inc, together worth $720 billion.
$4.14 trillion Assets Under Management (AUM)
As of 9th August 2024, Perceptive Advisors’s top holding is 10,794,876 shares of Cerevel Therapeutics Hldng I currently worth over $441 billion and making up 10.7% of the portfolio value.
In addition, the fund holds 28,057,456 shares of Amicus Therapeutics Inc worth $278 billion, whose value fell 16.8% in the past six months.
The third-largest holding is Arcellx Inc worth $215 billion and the next is Iovance Biotherapeutics Inc worth $208 billion, with 25,933,142 shares owned.
Currently, Perceptive Advisors's portfolio is worth at least $4.14 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Perceptive Advisors
The Perceptive Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Joseph Edelman serves as the Managing Member at Perceptive Advisors.
Recent trades
In the most recent 13F filing, Perceptive Advisors revealed that it had opened a new position in
Contineum Therapeutics Inc and bought 1,566,668 shares worth $27.6 billion.
The investment fund also strengthened its position in Iovance Biotherapeutics Inc by buying
6,660,151 additional shares.
This makes their stake in Iovance Biotherapeutics Inc total 25,933,142 shares worth $208 billion.
Iovance Biotherapeutics Inc soared 54.6% in the past year.
On the other hand, there are companies that Perceptive Advisors is getting rid of from its portfolio.
Perceptive Advisors closed its position in Inhibrx on 16th August 2024.
It sold the previously owned 4,256,104 shares for $149 billion.
Joseph Edelman also disclosed a decreased stake in Arcellx Inc by approximately 0.1%.
This leaves the value of the investment at $215 billion and 3,889,739 shares.
One of the largest hedge funds
The two most similar investment funds to Perceptive Advisors are Magnetar and Raymond James Trust N.a. They manage $4.14 trillion and $4.12 trillion respectively.
Joseph Edelman investment strategy
Perceptive Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 58.2% of
the total portfolio value.
The fund focuses on investments in the United States as
49.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only 3.8% of the portfolio.
The average market cap of the portfolio companies is close to $4.84 billion.
The complete list of Perceptive Advisors trades based on 13F SEC filings
These positions were updated on August 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Cerevel Therapeutics Hldng I |
No change
10,794,876
|
$441,402,480,000 | 10.65% |
| Amicus Therapeutics Inc |
No change
28,057,456
|
$278,329,964,000 | 6.72% |
| Arcellx Inc |
1.11%
3,889,739
|
$214,674,695,000 | 5.18% |
| Iovance Biotherapeutics Inc |
34.56%
25,933,142
|
$207,983,798,000 | 5.02% |
| Nuvalent Inc |
8.42%
2,549,077
|
$193,372,981,000 | 4.67% |
| Inhibrx, Inc. |
Closed
4,256,104
|
$148,793,396,000 | |
| Fusion Pharmaceuticals Inc. |
Closed
6,825,395
|
$145,517,421,000 | |
| Rhythm Pharmaceuticals Inc. |
5.45%
3,446,579
|
$141,516,534,000 | 3.42% |
| Vaxcyte, Inc. |
3.63%
1,862,608
|
$140,645,530,000 | 3.39% |
| Soleno Therapeutics Inc |
4.24%
3,204,976
|
$130,763,021,000 | 3.16% |
| Intra-Cellular Therapies Inc |
62.64%
1,716,407
|
$117,556,715,000 | 2.84% |
| Immatics N.v |
76.46%
8,086,159
|
$93,961,168,000 | 2.27% |
| Neurocrine Biosciences, Inc. |
19.21%
649,909
|
$89,472,972,000 | 2.16% |
| Apogee Therapeutics Inc |
2.20%
2,105,636
|
$82,856,776,000 | 2.00% |
| Madrigal Pharmaceuticals Inc |
38.46%
264,600
|
$74,130,336,000 | 1.79% |
| Artivion Inc |
4.67%
2,793,703
|
$71,658,482,000 | 1.73% |
| Spyre Therapeutics Inc |
18.55%
3,031,018
|
$71,259,233,000 | 1.72% |
| Sarepta Therapeutics Inc |
Closed
525,683
|
$68,054,921,000 | |
| Crinetics Pharmaceuticals In |
No change
1,476,203
|
$66,119,132,000 | 1.60% |
| Evolus Inc |
No change
5,753,798
|
$62,428,708,000 | 1.51% |
| SpringWorks Therapeutics, Inc. |
26.94%
1,652,962
|
$62,267,079,000 | 1.50% |
| Cargo Therapeutics Inc |
6.82%
3,683,004
|
$60,474,925,000 | 1.46% |
| Astria Therapeutics Inc |
No change
6,485,420
|
$59,017,322,000 | 1.42% |
| Natera Inc |
30.01%
530,000
|
$57,393,700,000 | 1.39% |
| Verrica Pharmaceuticals Inc |
No change
7,099,182
|
$51,753,037,000 | 1.25% |
| Biohaven Ltd |
13.90%
1,485,232
|
$51,552,403,000 | 1.24% |
| Immunovant Inc |
35.08%
1,923,786
|
$50,787,950,000 | 1.23% |
| Meiragtx Hldgs Plc |
No change
11,331,103
|
$47,667,625,000 | 1.15% |
| Protagonist Therapeutics Inc |
27.60%
1,268,735
|
$43,961,668,000 | 1.06% |
| Solid Biosciences Inc |
No change
6,906,646
|
$39,160,682,000 | 0.95% |
| Celcuity Inc |
No change
2,362,279
|
$38,694,130,000 | 0.93% |
| Medtronic Plc |
65.68%
490,665
|
$38,620,242,000 | 0.93% |
| Viking Therapeutics Inc |
27.43%
721,377
|
$38,240,195,000 | 0.92% |
| Applied Therapeutics, Inc. |
No change
8,005,000
|
$37,383,350,000 | 0.90% |
| Axsome Therapeutics Inc |
58.46%
459,111
|
$36,958,436,000 | 0.89% |
| Centessa Pharmaceuticals Plc |
27.57%
3,933,307
|
$35,517,762,000 | 0.86% |
| Tarsus Pharmaceuticals, Inc. |
No change
1,296,416
|
$35,236,587,000 | 0.85% |
| Verona Pharma Plc |
35.30%
2,433,725
|
$35,191,664,000 | 0.85% |
| Akero Therapeutics Inc |
8.10%
1,499,897
|
$35,187,584,000 | 0.85% |
| Edgewise Therapeutics Inc |
19.97%
1,856,417
|
$33,434,070,000 | 0.81% |
| Landos Biopharma Inc |
Closed
1,486,991
|
$31,940,566,000 | |
| Acrivon Therapeutics Inc |
78.23%
5,360,858
|
$31,092,976,000 | 0.75% |
| Praxis Precision Medicines I |
8.69%
750,230
|
$31,029,513,000 | 0.75% |
| Adma Biologics Inc |
56.93%
2,771,000
|
$30,979,780,000 | 0.75% |
| BridgeBio Pharma Inc |
13.93%
1,215,346
|
$30,784,714,000 | 0.74% |
| Aldeyra Therapeutics Inc |
7.94%
9,275,851
|
$30,703,067,000 | 0.74% |
| Treace Med Concepts Inc |
Closed
2,304,954
|
$30,079,650,000 | |
| Nautilus Biotechnology Inc |
No change
12,594,211
|
$29,470,453,000 | 0.71% |
| Autolus Therapeutics plc |
Closed
4,330,745
|
$27,630,153,000 | |
| Contineum Therapeutics Inc |
Opened
1,566,668
|
$27,589,023,000 | 0.67% |
| Intuitive Surgical Inc |
39.29%
61,800
|
$27,491,730,000 | 0.66% |
| Arvinas Inc |
16.89%
1,027,749
|
$27,358,678,000 | 0.66% |
| Rocket Pharmaceuticals Inc |
30.79%
1,246,597
|
$26,839,233,000 | 0.65% |
| Disc Medicine Inc |
41.12%
553,437
|
$24,943,406,000 | 0.60% |
| LivaNova PLC |
48.49%
444,000
|
$24,340,080,000 | 0.59% |
| Cg Oncology Inc |
43.74%
733,695
|
$23,162,751,000 | 0.56% |
| Xenon Pharmaceuticals Inc |
34.63%
583,256
|
$22,741,151,000 | 0.55% |
| Ocular Therapeutix Inc |
No change
3,324,468
|
$22,739,361,000 | 0.55% |
| Pepgen Inc |
No change
1,410,438
|
$22,510,590,000 | 0.54% |
| Viridian Therapeutics Inc |
55.38%
1,631,828
|
$21,230,082,000 | 0.51% |
| Orchestra Biomed Hldgs Inc |
No change
2,545,881
|
$20,748,930,000 | 0.50% |
| Revolution Medicines Inc |
Closed
618,885
|
$19,946,664,000 | |
| Abbvie Inc |
Closed
106,500
|
$19,393,650,000 | |
| Merus N.V |
Opened
300,000
|
$17,751,000,000 | 0.43% |
| Rapport Therapeutics Inc |
Opened
748,183
|
$17,402,737,000 | 0.42% |
| Moonlake Immunotherapeutics |
Closed
339,012
|
$17,028,573,000 | |
| Tyra Biosciences Inc |
50.54%
1,007,367
|
$16,107,798,000 | 0.39% |
| Inhibrx Biosciences Inc |
Opened
1,064,026
|
$15,077,248,000 | 0.36% |
| Arcutis Biotherapeutics Inc |
107.80%
1,558,500
|
$14,494,050,000 | 0.35% |
| Athira Pharma, Inc. |
No change
5,402,964
|
$14,317,855,000 | 0.35% |
| Zymeworks Inc |
55.16%
1,667,711
|
$14,192,221,000 | 0.34% |
| Cullinan Therapeutics Inc |
Opened
749,916
|
$13,078,535,000 | 0.32% |
| Procept Biorobotics Corp |
No change
210,659
|
$12,869,158,000 | 0.31% |
| Insmed Inc |
Opened
180,000
|
$12,060,000,000 | 0.29% |
| Bicycle Therapeutics plc |
Opened
572,000
|
$11,577,280,000 | 0.28% |
| RAPT Therapeutics, Inc. |
Closed
1,223,472
|
$10,986,779,000 | |
| Morphic Hldg Inc |
Closed
288,221
|
$10,145,379,000 | |
| Icon Plc |
Opened
31,250
|
$9,795,938,000 | 0.24% |
| Tempus Ai Inc |
Opened
275,000
|
$9,625,000,000 | 0.23% |
| Arrivent Biopharma Inc |
No change
415,000
|
$7,698,250,000 | 0.19% |
| Engene Holdings Inc |
19.91%
800,000
|
$7,544,000,000 | 0.18% |
| Ars Pharmaceuticals Inc |
No change
867,319
|
$7,380,885,000 | 0.18% |
| Argenx Se |
Opened
15,600
|
$6,708,624,000 | 0.16% |
| Allogene Therapeutics Inc |
Opened
2,725,000
|
$6,349,250,000 | 0.15% |
| Veru Inc |
26.48%
7,063,277
|
$5,942,335,000 | 0.14% |
| Cogent Biosciences, Inc. |
Closed
883,333
|
$5,935,998,000 | |
| KalVista Pharmaceuticals Inc |
No change
500,000
|
$5,890,000,000 | 0.14% |
| Recursion Pharmaceuticals In |
Opened
769,230
|
$5,769,225,000 | 0.14% |
| Immunitybio Inc |
Closed
1,052,887
|
$5,654,003,000 | |
| EyePoint Pharmaceuticals Inc |
8.59%
640,274
|
$5,570,384,000 | 0.13% |
| Macrogenics Inc |
Closed
378,327
|
$5,568,973,000 | |
| Helix Acquisition Corp Ii |
No change
500,000
|
$5,110,000,000 | 0.12% |
| Mereo BioPharma Group plc |
Opened
1,253,250
|
$4,511,700,000 | 0.11% |
| Cabaletta Bio Inc |
65.92%
585,045
|
$4,376,137,000 | 0.11% |
| Establishment Labs Holdings Inc |
Closed
82,299
|
$4,189,019,000 | |
| Precision BioSciences, Inc. |
11.28%
426,293
|
$4,147,831,000 | 0.10% |
| Newamsterdam Pharma Company |
Closed
175,000
|
$4,138,750,000 | |
| Skye Bioscience Inc |
Opened
500,000
|
$4,005,000,000 | 0.10% |
| Trinity Biotech Plc |
No change
1,800,000
|
$3,834,000,000 | 0.09% |
| iRhythm Technologies Inc |
85.64%
35,205
|
$3,789,466,000 | 0.09% |
| Lyra Therapeutics, Inc. |
No change
12,757,562
|
$3,533,844,000 | 0.09% |
| Biodesix Inc |
Opened
2,173,880
|
$3,326,036,000 | 0.08% |
| Envveno Medical Corporation |
No change
623,315
|
$3,272,404,000 | 0.08% |
| Foghorn Therapeutics Inc. |
Opened
544,000
|
$3,128,000,000 | 0.08% |
| Nanobiotix |
No change
555,066
|
$2,775,330,000 | 0.07% |
| Absci Corporation |
No change
700,000
|
$2,156,000,000 | 0.05% |
| Spdr Ser Tr |
Opened
22,665
|
$2,101,272,000 | 0.05% |
| X4 Pharmaceuticals, Inc. |
No change
3,545,454
|
$2,056,363,000 | 0.05% |
| Forte Biosciences, Inc. |
No change
3,265,359
|
$1,753,498,000 | 0.04% |
| Revance Therapeutics Inc |
No change
600,000
|
$1,542,000,000 | 0.04% |
| Structure Therapeutics Inc |
Opened
34,852
|
$1,368,638,000 | 0.03% |
| Fate Therapeutics Inc |
Opened
345,575
|
$1,133,486,000 | 0.03% |
| Kyverna Therapeutics Inc |
No change
150,000
|
$1,125,000,000 | 0.03% |
| Singular Genomics Systems In |
Closed
2,126,893
|
$1,093,648,000 | |
| Kura Oncology Inc |
Closed
48,200
|
$1,028,106,000 | |
| Eagle Pharmaceuticals Inc |
Opened
173,365
|
$970,844,000 | 0.02% |
| Amylyx Pharmaceuticals Inc |
Closed
300,000
|
$852,000,000 | |
| Vbi Vaccines Inc Cda |
No change
1,261,710
|
$832,728,000 | 0.02% |
| Tactile Sys Technology Inc |
93.06%
62,639
|
$747,910,000 | 0.02% |
| Syros Pharmaceuticals Inc. |
No change
116,754
|
$602,451,000 | 0.01% |
| Singular Genomics Systems In |
Opened
70,896
|
$599,071,000 | 0.01% |
| Caremax Inc |
No change
122,643
|
$342,174,000 | 0.01% |
| Axogen Inc. |
98.04%
30,421
|
$220,248,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 123 holdings | |||
Hedge funds similar to Perceptive Advisors
- Rokos Capital Management LL.P.
- Nan Shan Life Insurance Co
- Cerberus Capital Management, L.P.
- Interocean Capital
- Kingsview Wealth Management
- Advent International, L.P.
- Curi Rmb Capital
- Magnetar
- Raymond James Trust N.a
- Dai-ichi Life Insurance , Ltd
- Trian Fund Management, L.P.
- Bpifrance S.A.
- Coldstream Capital Management Inc
- Steadfast Capital Management L.P.